Advertisement
Person › Details
Beth DelGiacco (Argenx SE (Euronext + Nasdaq: ARGX))
DelGiacco, Beth (Argenx 201806– VP Investor Relations before Stern IR)
Organisation | Argenx SE (Euronext + Nasdaq: ARGX) | |
Group | Argenx (Argen-X) (Group) | |
Former/major organisation | Stern Investor Relations Inc. (Stern IR) | |
Group | Precision Medicine Group (Group) | |
Product | public relations / investor relations / marcom (services) | |
Product 2 | SIMPLE Antibody™ discovery platform | |
Argenx SE. (3/4/19). "Press Release: Argenx to Present at Cowen and Company 39th Annual Health Care Conference". Breda & Ghent.
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 12:00 p.m. ET in Boston.
A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.
www.argenx.com
For further information, please contact:
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Beth DelGiacco, VP Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should” and include statements argenx makes concerning the intended results of its strategy and argenx’s advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts, related to cusatuzumab. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Record changed: 2023-04-17 |
Advertisement
More documents for Beth DelGiacco
- [1] Argenx SE. (8/8/22). "Press Release: Argenx Announces European Commission Approval of Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis"....
- [2] Argenx SE. (3/29/22). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda....
- [3] Argenx SE. (12/20/21). "Press Release: Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Darmstadt....
- [4] Argenx SE. (9/3/21). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda....
- [5] Argenx SE. (7/14/21). "Press Release: Argenx to Host Virtual R&D Day on July 20, 2021". Breda....
- [6] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
- [7] Argenx SE. (1/4/21). "Press Release: Argenx to Present at 39th Annual J.P. Morgan Healthcare Conference". Breda & Ghent....
- [8] Argenx SE. (10/6/20). "Press Release: Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships". Breda & Ghent....
- [9] Argenx SE. (5/29/20). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda & Ghent....
- [10] Argenx SE. (5/28/20). "Press Release: Argenx Raises $750 Million in Gross Proceeds in a Global Offering". Breda & Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top